World CNS Summit South Korea 2026 | CNS CRO for Biotechs

Why CNS Biotechs Should Choose Avance Clinical’s CNS Center of Excellence

CNS trial design backed by real-world experience

Avance Clinical has completed more than 50 CNS trials in the past five years, across neurodegenerative disease, mood disorders, neurodevelopmental conditions, and chronic pain.

Our CNS team brings that experience to protocol design from day one, shaping studies around heterogeneous patient populations and challenging endpoints with practical attention to inclusion criteria, enrichment strategy, endpoint selection, visit schedules, and caregiver burden, reducing screen failure, limit attrition, and avoid costly amendments later in development.

Seamless pathway from Australia Early Phase to Asia and beyond

Avance Clinical supports globally minded CNS biotechs with an expanding operational footprint that includes key Asian hubs such as South Korea and Taiwan.

This access to diverse patient populations, regional scientific infrastructure, and accelerated clinical trial timelines allows Asia-based and global sponsors to leverage Australia’s early-phase advantages and R&D incentives, then scale efficiently into later-phase, multi-regional CNS trials across the region and beyond.

One partner across Australia, Asia, China, and North America

Through our GlobalReady model, biotech sponsors work with a single CRO from first-in-human through later-phase, multi-country studies, with aligned teams, harmonized processes, and consistent data standards across Australia, Asia, and other key regions.

This reduces handoffs, preserves program knowledge, and keeps investigator relationships and rater training intact as a CNS program moves from proof-of-concept into larger, later-phase trials.